commercialisation

Market Access

Blue and white pills in pharma manufacturing line

Pharma’s most expensive question is the last one asked

Whether a drug can secure reimbursement is pharma's billion-dollar question, and the companies that succeed will be those that answer it sooner.

Sales & Marketing

Omnideployment concept, female hand holds digital globe and connected networks of men and women

Beyond omnichannel: Why pharma commercialisation must shift ...

We need to step away from the passive, broad concept of omnichannel and adopt a far more active, disciplined framework: omnideployment.

News

Roche’s Genentech strikes $2.3bn deal for Hanmi obesity drug...

Roche’s Genentech has agreed a deal worth up to $2.3 billion to develop and sell Hanmi Pharmaceutical’s experimental obesity drug HM17321.

Market Access

The new commercialisation playbook: What BIO 2026 taught eme...

BIO International focused on how emerging biotech companies should approach their first product launch outside the United States, typically in Europe.

Sales & Marketing

Why Medical Affairs must be integrated into field strategy

Many organisations still operationalise Medical Affairs as a downstream contributor, rather than an integrated strategic partner.

Market Access

Company Profile: Acumetis

Acumetis is a global expert commercialisation partner purposefully built to help life sciences companies win in the age of connectivity.

Pharma’s most expensive question is the last one asked

Beyond omnichannel: Why pharma commercialisation must shift ...

Roche’s Genentech strikes $2.3bn deal for Hanmi obesity drug...

The new commercialisation playbook: What BIO 2026 taught eme...

Why Medical Affairs must be integrated into field strategy

Company Profile: Acumetis

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

commercialisation

Editor's Picks